Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Date:12/13/2011

CAMBRIDGE, Mass., Dec. 13, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with cetuximab (Erbitux®) and irinotecan (Camptosar®) in patients with advanced cancers.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab and irinotecan in patients with advanced colorectal cancer, squamous cell head and neck cancer, non-small cell lung cancer, triple negative breast cancer, or other types of solid tumors that depend on epidermal growth factor receptor (EGFR) activity. Multiple centers across the United States are expected to participate in this study. The first patient was enrolled at the Huntsman Cancer Institute at the University of Utah in Salt Lake City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 The global dental bone ... a CAGR of 10.6% within a forecast period from ... bn in 2013. Owing to favorable factors at play ... bn by the end of this forecast period, i.e. ... holistic representation in a research report published by Transparency ...
(Date:5/31/2016)... NESS ZIONA, Israel , ... a regenerative medicine company utilizing its proprietary plant-based rhCollagen ... has received authorization from the Chief Scientist of ... approximately 50% of its NIS 12 million development project ... million, measurably higher than last year,s authorized grant, which ...
(Date:5/30/2016)... , May 30, 2016 ... research report "Healthcare Biometrics Market by Technology ... Voice)), Multifactor, Multimodal), Application (Workforce Management), End ... to 2021", published by MarketsandMarkets, the market ... by 2021 from USD 1,182.6 Million by ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... May 31, 2016 , ... Throughout the day, adults often find themselves reaching ... and awareness, but what they could be reaching for instead is a cup of Matcha ... are grown in Japan. This sacred tea is harvested from early June to mid-July, when ...
(Date:5/31/2016)... ... May 31, 2016 , ... Presence ... it has been included by Gartner, Inc. in the Contact Center Infrastructure Magic ... Contact Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services ...
(Date:5/31/2016)... TEXAS (PRWEB) , ... May 31, 2016 , ... ... live in Greater Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians ... medical records for their patients from other participating organizations in the exchange. SJMC’s ...
(Date:5/31/2016)... GA (PRWEB) , ... May 31, 2016 , ... ... readmissions using a mix of advanced Artificial Intelligence (AI) and the latest in ... solution. The medical center is integrating predictive analytic outputs directly into the clinical ...
(Date:5/31/2016)... ... 31, 2016 , ... DDL, Inc. announced today it has expanded the scope ... include ISO 594-1 and ISO 594-2 testing for conical (Luer) fittings. , A ... two medical devices (e.g. a syringe and hypodermic needle) that carry small volumes of ...
Breaking Medicine News(10 mins):